1. Home
  2. CTRM vs CTXR Comparison

CTRM vs CTXR Comparison

Compare CTRM & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

HOLD

Current Price

$1.75

Market Cap

21.2M

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.83

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTRM
CTXR
Founded
2016
2007
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.2M
18.9M
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
CTRM
CTXR
Price
$1.75
$0.83
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
40.1K
562.5K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.38
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.66
$0.63
52 Week High
$2.65
$2.38

Technical Indicators

Market Signals
Indicator
CTRM
CTXR
Relative Strength Index (RSI) 32.23 51.70
Support Level $1.66 $0.68
Resistance Level $2.20 $0.98
Average True Range (ATR) 0.11 0.07
MACD -0.01 0.01
Stochastic Oscillator 20.00 58.15

Price Performance

Historical Comparison
CTRM
CTXR

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: